GM04601 clone 21, GM04601-21
CBRCULi012-A
General
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Disease associated phenotypes |
|
| Family history | The donor have clinically affected mother and sister |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
External Databases (Donor) |
|
| BioSamples | SAMN00795392 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Please provide the contact information | https://www.coriell.org/ |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Unknown |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent pertain to a specific research project? | No |
| Does consent expressly prevent development of commercial products? | Yes |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | |
| Approval number | |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | CHUQ Ethical Committee |
| Approval number | 2018-4172 |
| Is there an MTA available for the cell line? | Yes |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
hIPSC Derivation
General |
|
| Source cell line name | GM04601 (CBRCULi012-A) |
| Source cell type |
Synonyms
|
| Source cell origin |
An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.
Synonyms
|
| Source cell line vendor | Coriell Institute for Medical Research |
| Passage number reprogrammed | 5 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Methods used |
RT-PCR
|
| Notes on reprogramming vector detection | Vector detection carried on cells at P23 |
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| Medium |
mTeSR™ Plus
|
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
|||||
| SOX2 |
Yes |
|||||
| TRA 1-60 |
Yes |
|||||
| SSEA-4 |
Yes |
|||||
| TRA 1-81 |
Yes |
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
Morphology pictures
Phase contrast iPSC morphology. Scale : 200 μm
Differentiation Potency
In vitro directed differentiation
In vitro directed differentiation
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Certificate of Analysis |
|
| Is there a certificate of analysis available? |
Yes
Passage:
|
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46 XX Normal
Passage number: 6
Karyotyping method:
Molecular karyotyping by SNP array
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.